1474 related articles for article (PubMed ID: 26565927)
1. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
2. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
[TBL] [Abstract][Full Text] [Related]
4. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
5. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
[TBL] [Abstract][Full Text] [Related]
6. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.
Maguire MG; Liu D; Glassman AR; Jampol LM; Johnson CA; Baker CW; Bressler NM; Gardner TW; Pieramici D; Stockdale CR; Sun JK;
JAMA Ophthalmol; 2020 Mar; 138(3):285-293. PubMed ID: 31999300
[TBL] [Abstract][Full Text] [Related]
7. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
9. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
[TBL] [Abstract][Full Text] [Related]
10. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Diabetic Retinopathy Clinical Research Network*
JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
[TBL] [Abstract][Full Text] [Related]
12. PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Retina; 2019 Sep; 39(9):1646-1654. PubMed ID: 30807516
[TBL] [Abstract][Full Text] [Related]
13. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
[TBL] [Abstract][Full Text] [Related]
14. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
Baker CW; Glassman AR; Beaulieu WT; Antoszyk AN; Browning DJ; Chalam KV; Grover S; Jampol LM; Jhaveri CD; Melia M; Stockdale CR; Martin DF; Sun JK;
JAMA; 2019 May; 321(19):1880-1894. PubMed ID: 31037289
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
[TBL] [Abstract][Full Text] [Related]
16. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK; Glassman AR; Josic K; Baker CW; Gerstenblith AT; Jampol LM; Meleth A; Martin DF; Melia M; Punjabi OS; Rofagha S; Salehi-Had H; Stockdale CR; Sun JK;
JAMA; 2023 Feb; 329(5):376-385. PubMed ID: 36749332
[TBL] [Abstract][Full Text] [Related]
17. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
18. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Beaulieu WT; Maguire MG; Antoszyk AN; Chow CC; Elman MJ; Jampol LM; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):725-733. PubMed ID: 33956075
[TBL] [Abstract][Full Text] [Related]
19. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
